Clinical characteristics and treatment outcomes in HIV-1/HBV co-infected Kenyan women.

HBeAg, hepatitis B e antigen. HBV, hepatitis B virus.aHBV DNA Suppression defined as ≤100 IU/mL.bUpper limit of normal for ALT assay is 17 U/L.cMean adherence calculated from pill count across all visits. If pill count unavailable, used patient recall of pills taken.dQuantity n/s, quantity not sufficient for baseline genotype analysis.eIf HBV DNA fThis woman seroconverted for HBeAg at day 87 of ART.gThis woman developed ALT elevations and had to discontinue ART at day 58; she resumed at day 334 and initially suppressed HBV DNA at day 392; she was noted to have poor adherence and HBV DNA relapse at day 456.hHad baseline mutation V173L.iThis woman developed the M204I lamivudine resistance mutation at day 392 of ART; the lowest HBV DNA level achieved was 1100 IU/mL at day 1320 of ART.jThis woman was noted to have poor adherence (88%); the lowest HBV DNA level achieved was 44,000 IU/mL at day 351 of ART.